NCT05714553 2025-07-18
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
NuCana plc
Phase 1/2 Terminated
Clinical Trials
26 trialsNCT00253318 2025-04-27
RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancer
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT06652607 2025-03-12
PSA-DEEP02
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Recruiting
NCT01879085 2022-09-21
GemTax
University of Pittsburgh
Phase 1/2 Completed
NCT02494921 2022-08-31
LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC
University of California, San Francisco
Phase 1/2 Completed
NCT02128243 2021-03-26
MATEO
AIO-Studien-gGmbH
Phase 2 Completed
NCT00582582 2019-12-13
Study of Docetaxel With Doxercalciferol or Placebo for Advanced Prostate Cancer
University of Wisconsin, Madison
Phase 2 Terminated
NCT00979641 2019-03-28
AINO
Tampere University Hospital
Phase 2 Terminated
NCT02007148 2019-02-27
MICADO
International Group of Endovascular Oncology
Phase 2 Unknown
NCT00428922 2018-08-09
Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV Metastatic Breast Cancer (MBC) Patients
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT01385228 2018-06-06
Pazopanib, Docetaxel, Prednisone Prostate
Duke University
Phase 1 Completed
NCT02793765 2017-10-30
Docetaxel Followed by Provenge in Metastatic Prostate Cancer
The University of Texas Health Science Center, Houston
Phase 2 Withdrawn
NCT02474186 2017-08-03
Phase II Study for Solid Metastatic Tumors
NYU Langone Health
Phase 2 Completed
NCT03147963 2017-05-10
Docetaxel 2-weeks Regimen in the Treatment of HER2 Negative Metastatic Breast Cancer
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT00190489 2016-09-02
A Trial of Doxorubicin/Cyclophosphamide (AC), Docetaxel (D), and Alternating AC and D for Metastatic Breast Cancer
Japan Clinical Oncology Group
Phase 3 Completed
NCT00459186 2016-05-16
The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT00390416 2016-03-14
Study of Docetaxel, Cisplatin, and Fluorouracil (Modified DCF) With Bevacizumab in Patients With Unresectable or Metastatic Gastroesophageal Adenocarcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00377559 2015-10-06
MYOTAX
Catharina Ziekenhuis Eindhoven
Phase 2 Completed
NCT00377780 2015-09-23
MYOHERTAX
Catharina Ziekenhuis Eindhoven
Phase 2 Terminated
NCT00378404 2015-06-08
Phase I Trial of Docetaxel and Low-Dose Fractionated Radiation in the Treatment of Metastatic or Recurrent NSCLC
University of Kentucky
Phase 1 Terminated
NCT01069081 2015-03-06
Docetaxel and Cisplatin Chemotherapy With or Without High Dose Proton Pump Inhibitor in Metastatic Breast Cancer
Fudan University
Phase 2 Completed
NCT00084825 2012-10-26
Docetaxel and Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases That Progressed on the Docetaxel and Placebo Group of MDA-ID-030008
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00080678 2012-10-12
Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00232206 2011-05-18
Trial of Neoadjuvant Docetaxel and Cisplatin for Resectable Non-Small Cell Lung Cancer
Providence Health & Services
Phase 2 Terminated
NCT00541281 2009-10-27
Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase 2 Completed
NCT00142038 2007-04-18
Docetaxel and Capecitabine in Advanced Gastric Cancer
Charite University, Berlin, Germany
Phase 2 Completed